share_log

Predictmedix Announces Production of AI-Powered Mobile Application to Rapidly Detect Impairment From Alcohol and Cannabis

Predictmedix Announces Production of AI-Powered Mobile Application to Rapidly Detect Impairment From Alcohol and Cannabis

Predictmedix 宣布生产人工智能驱动的移动应用程序,以快速检测酒精和大麻造成的损害
Accesswire ·  2023/03/15 19:05
  • Predictmedix has begun production of its mobile application for detecting impairment from cannabis and alcohol
  • Predictmedix's screening to identify impairment takes less than 30 seconds
  • The mobile application, powered by AI algorithms currently being utilized in Safe Entry will be accompanied by a "mini" multi-spectral imaging camera resulting in a portable non-invasive impairment detection solution
  • Commercialization will specifically target Law Enforcement, Transport, and other mobile high-risk industries
  • Predictmedix已开始生产其移动应用程序,用于检测大麻和酒精造成的损害
  • Predictmedix 进行筛查以识别损伤所需的时间不到 30 秒
  • 该移动应用程序由目前在Safe Entry中使用的人工智能算法提供支持,将配备 “微型” 多光谱成像摄像机,从而提供便携式非侵入性损伤检测解决方案
  • 商业化将专门针对执法、运输和其他移动高风险行业

TORONTO, ON / ACCESSWIRE / March 15, 2023 / Predictmedix Inc. ("Predictmedix" or the "Company") (CSE:PMED) (OTCQB:PMEDF) (FRA:3QP), an emerging provider of rapid health screening solutions powered by a proprietary artificial intelligence (AI), today announced the production of its AI-Powered mobile app in conjunction with a portable multi-spectral imaging camera to non-invasively detect impairment from alcohol and cannabis. The non-invasive solution will be commercialized with the intent to serve global law enforcement agencies, transport, and other mobile high-risk industries where impairment remains a significant liability. The Company's recently conducted studies showed that its screening tool can accurately identify impaired individuals with a success rate of over 90%. Furthermore, the screening process takes less than 30 seconds to complete, making it a quick and reliable way to identify impairment. Although cannabis breathalyzers are still at an early stage of development, alcohol breathalyzers have been reported to have up to a 50% margin of error according to the National Motorists Association1.

安大略省多伦多/ACCESSWIRE/2023 年 3 月 15 日/ 由专有人工智能(AI)提供支持的快速健康筛查解决方案的新兴提供商Predictmedix Inc.(“Predicmedix” 或 “公司”)(CSE: PMED)(OTCQB: PMEDF)(FRA: 3QP)今天宣布生产其人工智能驱动的移动应用程序以及便携式多光谱成像相机,用于无创地检测酒精和大麻造成的损伤。这种非侵入性解决方案将商业化,旨在为全球执法机构、运输和其他移动高风险行业提供服务,在这些行业中,减值仍然是一项重大负担。该公司最近进行的研究表明,其筛查工具可以准确识别受损个人,成功率超过90%。此外,筛查过程只需不到 30 秒即可完成,这使其成为识别损伤的快速可靠方法。尽管大麻呼吸分析仪仍处于开发的初期阶段,但据报道,根据全国驾车者协会的数据,酒精呼吸分析仪的误差幅度高达50%1

Impairment from alcohol and cannabis has been an ongoing issue for law enforcement and high-risk industries around the world - and current testing protocols are long, costly, and onerous. Drug testing companies have failed to create a product that is reliable, quick, cost-effective, and non-invasive all in one product. Predictmedix's portable solution intended for law enforcement agencies and other high-risk mobile industries addresses the problems that companies and organizations have been facing for many years.

酒精和大麻减值一直是世界各地执法部门和高风险行业持续面临的问题——而且目前的测试协议漫长、昂贵且繁重。药物测试公司未能创造出可靠、快速、具有成本效益和非侵入性的多合一产品。Predictmedix的便携式解决方案适用于执法机构和其他高风险移动行业,解决了公司和组织多年来面临的问题。

A multiparametric approach is used to identify unique and specific features based on facial and speech analysis which are analyzed by AI algorithms, resulting in an un-biased outcome. The multi-spectral imaging camera captures non-visible wavelength data which the AI algorithms extract features that are associated with impairment from alcohol and/or cannabis. AI by nature is self-learning, Predictmedix's algorithms improve as more data is obtained and processed resulting in greater accuracy and speed with time.

使用多参数方法根据面部和语音分析识别独特和具体的特征,这些分析由人工智能算法进行分析,从而得出不偏不倚的结果。多光谱成像摄像机可捕获不可见的波长数据,人工智能算法提取这些数据与酒精和/或大麻损害相关的特征。人工智能本质上是自我学习的,随着获得和处理的数据越来越多,Predictmedix的算法会不断改进,从而随着时间的推移提高准确性和速度。

Although the combination of both multispectral imaging and speech analysis has resulted in an accuracy of over 90% to identify impaired individuals, the Speech Analysis component of the solution by itself has achieved an impressive accuracy rate in identifying impairment. Predictmedix is cognizant of the potential this specific use-case has for the end consumer and is currently taking action to preserve the rights and IP of the technology for commercialization efforts and shareholder concerns.

尽管将多光谱成像和语音分析相结合,使识别受损个体的准确度超过90%,但该解决方案的语音分析组件本身在识别损伤方面取得了令人印象深刻的准确率。Predictmedix意识到这种特定用例对最终消费者具有的潜力,目前正在采取行动保护该技术的权利和知识产权,以应对商业化工作和股东的担忧。

"We are happy to announce to our shareholders that we are making very good progress with our portable solution for detecting impairment in individuals. From our research and discussions with high-level contacts, we believe our product will be in high demand in multiple industry verticals worldwide. In 2021, the drug screening market size was valued at over $5.2 Billion with revenue forecasted at over $22 Billion in 20302, making this another lucrative opportunity for Predictmedix," commented Dr. Rahul Kushwah, Chief Operating Officer at Predictmedix. "We look forward to updating our shareholders on further technological and commercial development."

“我们很高兴地向股东宣布,我们在检测个人减值的便携式解决方案方面取得了非常好的进展。从我们的研究和与高层联系人的讨论来看,我们相信我们的产品将在全球多个垂直行业中受到很高的需求。2021年,药物筛查市场规模超过52亿美元,预计2030年的收入将超过220亿美元2,这对于Predictmedix来说又是一个有利可图的机会。” Predictmedix首席运营官拉胡尔·库什瓦博士评论道。“我们期待向股东通报进一步的技术和商业发展的最新情况。”

1

1

2

2

About Predictmedix Inc.

关于 Predicmedix Inc.

Predictmedix (CSE:PMED) (OTCQB:PMEDF) (FRA:3QP) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company's Safe Entry Stations - powered by a proprietary artificial intelligence (AI) - use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including infectious diseases such as COVID-19, impairment by drugs or alcohol, fatigue or various mental illnesses. Predictmedix's proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at or follow us on Twitter, Instagram or LinkedIn.

Predictmedix(CSE: PMED)(OTCQB: PMEDF)(FRA: 3QP)是全球快速健康筛查和远程患者护理解决方案的新兴提供商。该公司的安全进入站由专有的人工智能(AI)提供支持,使用多光谱摄像机分析生理数据模式并预测各种健康问题,包括 COVID-19 等传染病、药物或酒精损伤、疲劳或各种精神疾病。Predictmedix 专有的远程患者护理平台为医疗专业人员提供了一套人工智能驱动的工具,以改善患者的健康状况。要了解更多信息,请访问我们的网站或在推特、Instagram 或 LinkedIn 上关注我们。

Public Relations Contact

公共关系联系人

For further media information or to set up an interview, please contact:

欲了解更多媒体信息或安排采访,请联系:

Nelson Hudes
Hudes Communications International
(905) 660 9155

纳尔逊·哈德斯
Hudes 通讯国际
(905) 660 9155

Nelson@hudescommunications.com
Dr. Rahul Kushwah
(647) 889 6916

Nelson@hudescommunications.com
拉胡尔·库什瓦博士
(647) 889 6916

Caution Regarding Forward-Looking Information:

关于前瞻性信息的注意事项:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any Page 4 of 4 future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the Company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry.

本新闻稿可能包含前瞻性陈述和基于当前预期的信息。这些陈述不应被视为对公司未来业绩或业绩的保证。此类陈述涉及已知和未知的风险、不确定性和其他因素,这些因素可能导致实际业绩、业绩或成就与此类陈述所暗示的结果存在重大差异。尽管此类陈述基于管理层的合理假设,但无法保证此类假设会被证明是正确的。我们不负责更新或修改它们以反映新的事件或情况。公司的证券尚未根据经修订的1933年《美国证券法》(“美国证券法”)或适用的州证券法进行注册,如果没有注册或不受此类注册要求的适用豁免,则不得向在美国的人或 “美国个人”(该术语的定义见美国证券法的法规)发行或出售,也不得为他们的账户或利益发行或出售。本新闻稿不构成出售要约或招揽买入要约,也不得在美国或任何此类要约、招揽或出售非法的司法管辖区出售证券。此外,还有一些已知和未知的风险因素可能导致公司的实际业绩、业绩或成就与本文件所含前瞻性信息所表达或暗示的未来业绩、业绩或成就存在重大差异,例如但不限于依赖获得监管部门批准;获得与其技术相关的知识产权的能力;运营历史有限;一般商业、经济、竞争、政治、监管和社会不确定性,以及特别是与 COVID-19 相关的不确定性;与公司无法控制的因素相关的风险,包括与 COVID-19 相关的风险;与公司股票相关的风险,包括该方可能也可能无法控制的事件导致的价格波动;对管理层的依赖;以及该行业其他竞争对手的紧急情况。

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.

本文中的所有前瞻性信息均受本警示声明的全面限制,除非法律要求,否则公司不承担任何修改或更新任何此类前瞻性信息或公开宣布为反映未来业绩、事件或发展而对本文包含的任何前瞻性信息进行任何修订的结果的义务。

Disclaimer: "The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time."

免责声明:“公司目前没有明示或暗示地声称其产品能够诊断、消除、治愈或控制 COVID-19(或 SARS-2 冠状病毒)。”

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

加拿大证券交易所尚未审查本新闻稿的充分性或准确性,也不承担任何责任。

SOURCE: PredictMedix Inc.

来源: predicmedix Inc.


View source version on accesswire.com:
在 accesswire.com 上查看源代码版本:

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发